Growth Option

A growth option is the right—not the obligation—to invest in follow-on projects enabled by a current investment. A pharmaceutical company that successfully develops a drug platform gains the growth option to develop follow-on drugs. An oil company that proves reserves in a new region gains the growth option to develop adjacent fields. The value of these future opportunities is not captured by traditional discounted cash flow analysis, which focuses on the current project alone.

How growth options create value

A startup develops an AI translation system. The core business (selling translation software) has an NPV of $50 million. But the platform also opens doors: machine-learning on other language tasks, integration into other software products, licensing to enterprise customers. These follow-on opportunities are options—the startup can invest in them or not, depending on how the core project performs and market conditions shift.

If the startup exercises these options and they succeed, the total value might reach $500 million. If the core fails or markets don’t materialize, the startup exercises none and loses the option value. The growth option is the right, not the obligation, which is exactly what call options are.

Traditional DCF valuation models the core business’s cash flows and discounts them. It might miss the growth options entirely unless they are explicitly modeled as branching scenarios. A real options approach assigns a value to the flexibility to pursue follow-on investments, capturing value that DCF misses.

Valuation approaches

Scenario-based valuation estimates the probability and cash flows of follow-on projects. If Phase 1 of a project succeeds (probability 70%), the company can invest in Phase 2 (expected NPV $100M, cost $20M) with probability 60%. The growth option value is 0.70 × 0.60 × ($100M − $20M) = $33.6M. This is added to the Phase 1 NPV to get total project value.

Black-Scholes and variants adapt the option pricing model from financial options. The growth option is valued as a call option where:

• Strike price = cost of the follow-on investment
• Underlying asset = the follow-on project’s PV (present value of cash flows)
• Time to expiration = the window in which the company can decide to invest
• Volatility = uncertainty in the follow-on project’s value

A follow-on project with high volatility (uncertain outcomes) has higher option value because success pays off handsomely and failure is just not exercised. A certain, low-volatility follow-on project has lower option value—it will likely be done regardless, so the option aspect is less valuable.

Real-world examples

Pharmaceutical development: A company spends $1 billion on Phase I–III trials for a drug targeting diabetes. If successful, the drug might generate $5 billion in NPV. But the real prize is the growth option: the underlying biology and patient population enable development of related drugs (obesity, kidney disease, cardiovascular) worth potentially billions more. Much of the original investment’s value lies in this growth-option value, not the initial drug.

Real estate development: A developer builds a commercial shopping center on a 10-acre parcel, using 5 acres. The remaining 5 acres are optioned for future expansion. The growth option to expand if demand materializes is valuable; if demand is weak, the developer does not expand. This is why optioning land is often more valuable than building immediately.

Software platforms: Salesforce began with customer relationship management (CRM). The growth option to build adjacent products (marketing cloud, commerce cloud, analytics) and expand into enterprise services has driven much of its value. Each success opens new growth options. Traditional valuation of Salesforce’s core CRM business would have deeply undervalued the company.

Factors affecting growth-option value

Volatility: Higher uncertainty in follow-on project outcomes increases option value. A biotech stock with a binary drug-approval outcome has high volatility and high growth-option value. A utility with predictable earnings has low volatility and low growth-option value.

Time window: Options that expire soon are less valuable. A company with a 2-year window to exercise a follow-on investment has less option value than one with a 10-year window (assuming the same underlying value and volatility). This is why patent and regulatory exclusivity are valuable—they extend the time window.

Investment cost: Higher costs to exercise the option reduce its value (higher strike price). A growth option requiring $100M in follow-on investment is less valuable than one requiring $10M, all else equal.

Competitive dynamics: If competitors can also exercise similar growth options, the value is eroded. If a company has exclusive access (patent, first-mover advantage), growth-option value is higher.

Organizational implications

Companies with extensive growth options—biotech, software, tech platforms—should invest in the core project even if its standalone NPV is marginal, because the growth-option value is substantial. Conversely, commodities businesses with little strategic optionality should be disciplined about accepting only projects with strong immediate returns.

Growth options can also encourage organizational flexibility. If a project’s main value lies in growth options, the organization should be structured to adapt and respond to early results, rather than commit rigidly to a single path.

Relation to expansion and abandonment options

Growth options are closely related to expansion options (the right to expand a successful project) and abandonment options (the right to exit if unsuccessful). Together, they comprise the real options value of a strategic project. A staged venture capital fund structure—investing in tranches, with the right to increase or stop funding—explicitly uses growth and abandonment options as valuation levers.